Triveni Bio raises $115M Series B for antibody therapies targeting immunological disorders.
Triveni Bio, a biotech firm from Watertown, MA, has raised $115 million in Series B funding to enhance its antibody therapies targeting immunological disorders. Led by Goldman Sachs Alternatives, with contributions from Fidelity and Deep Track Capital, the funding will support the development of TRIV-509 for atopic dermatitis and TRIV-573 for other inflammatory conditions. An IND application for TRIV-509 is expected in early 2025.
October 02, 2024
3 Articles